Prioritisation

Public consultation on socio-economic impacts

The objective of this consultation is to inform policy makers about the economic and social consequences of the authorisation requirement. You are invited to provide specific information about the use of the substance and available alternatives, impacts on the environment, public health and society, and impacts on the supply chain and competitiveness.

This questionnaire contains 32 questions and is aimed at individuals, organisations, companies, as well as Member States. Due to the variation of the questions, it is possible that you are not able to answer to all of them.

Thank you for your contribution!

Substance

1. What is the name of the substance on which you comment. Please specify if your replies concern more than one substance, e.g. a group of substances with similar uses:

Uses

1. What is the use of the substance (sectors, types of uses, categories of products, etc.)?
	1. In general?
	2. By your company? *(only for companies)*
2. Can you specify the use in terms of volume/value?
3. Overall in the EU?
4. By your company? *(only for companies)*
5. What are the properties/functions of the substance on those uses/sectors?
6. Is the substance present in a finished article? If yes, at what concentration?

Environment and Health

1. Does the use of the substance imply any releases/exposure/risks for workers, consumers or environment?
2. What measures have been put in place to prevent these releases/exposure/risks?
3. How can exposure of workers or consumers be further reduced? How can releases into the environment be further minimised?
4. Are you aware of any relevant information (e.g. study or article) quantifying the cost of environmental or human health impacts related to the use of the substance?

Availability of alternatives

1. Are you aware about any alternative substances, processes or technologies currently available for the use(s) of the substance?
	1. If yes, what are these alternatives and where are they used?
	2. What are the main differences between using these alternatives compared to the substance in question (e.g. whether the alternative substance provides the function and, if so, whether there is any difference in the level of performance; in case of an alternative process or technology, the function may be redundant)?
	3. What are the hazard properties of the alternatives compared to the substance in question?
	4. Are the alternatives already available, i.e. drop-in alternatives? Or do their implementation require changes in the production process and investments?
	5. What is the expected price of alternatives, per unit (e.g. per kilo, tonne)?
	6. Would an alternative require the same, more or less volume (e.g. in kilos, tonnes) compared to the substance in question?
2. Would the use of these alternative substances, processes or technologies have a positive or negative impact, or no effect, on sustainability (considering the whole life cycle: manufacture of the substance/production/consumption/waste/recycling)?
3. Are you planning to substitute the substance? If so, by when? *(only for companies)*
4. Are there uses for which there are no alternatives (substances, processes or technologies)? If yes, could you explain why?
5. If there are no alternatives, are you aware of any research, development and innovation efforts attempting to develop them? If so, how long do you expect that the development / testing can take?
	1. In the EU or in non-EU countries?
	2. By your company? *(only for companies)*

Market and Supply Chain

1. Specifying the use of the substance, both overall in the EU and by your company, what is the annual volume/value of the substance:
	1. Placed on the EU market?
	2. Manufactured in the EU?
	3. Imported into the EU?
	4. Exported from the EU?
2. Could you specify the sector in which the substance is used and describe the supply chain, including your role in the supply chain?
3. Can you provide data on the turnover of the concerned sectors and the number of people employed? How much of these data is related to the EU market? What is the turnover of the substance/substance-related products vs. the total turnover of the sector?
4. Can you estimate the relative weight of SMEs in the concerned sectors (in terms of number of companies and employment) in your country /in the EU?
5. Are the manufacturers of the substance or downstream users concentrated in a single/limited number of Member States or in a limited number of regions?

Competitiveness

1. What would be, or has been, the overall cost and time of substitution for the particular use you are providing information on? This includes (if relevant) the need of changes in the production process, need for new product testing, qualification and certification, etc.
2. What is the expected impact of substitution costs on the costs of your inputs or final products? What is expected impact on your sales in the EU/outside the EU countries? *(only for companies)*
3. Please describe the typical length of the order cycle / investment cycle.
	1. To the concerned sectors?
	2. To your company? *(only for companies)*
4. Please describe what the impacts of including the substance in Annex XIV of REACH would be? This includes changes in the competitive position with respect to non-EU competitors in the EU market and in third markets.
5. To the concerned sectors?
6. To your company? *(only for companies)*

**Other impacts of inclusion in Annex XIV** (innovation and business opportunities)

1. If the substance is included in Annex XIV to be eventually phased out, would it create business opportunities (e.g. gaining new markets or higher market share, development of alternative substances / products / production techniques)?
	1. In your sector?
	2. For your company? *(only for companies)*
2. What effects do you expect on enterprises’ capacity to innovate? (The capacity to produce more efficiently and/or higher quality and a larger scale of products and services and the capacity to bring R&D to the market)
3. Are you aware of any likely effects on recycling or sustainability?
4. In your opinion, if the substance is included in Annex XIV to be eventually phased out, would the economy, society or the environment be better or worse off (all factors considered)? Why?

Application for authorisation *(only for industry actors)*

1. If the substance is included in Annex XIV, would you consider applying for an authorisation? Are you aware if your suppliers/downstream users would consider to apply?
2. How would you envisage that the submission of an application for authorisation could be organised, considering your specific uses and the structure of the supply chain: would you envisage an application by manufactures/importers of the substance or formulators (upstream the supply chain)/ or applications by downstream users or a combination of all)?
3. What main challenges in preparing an application do you expect for your specific case? Would you envisage applying for your own uses or would you apply to cover uses of your downstream users? Would you apply jointly with other downstream users covering the same use?

Regulatory options

1. Do you consider that other regulatory options could better address the concerns for human health or the environment for which the substance is recommended for inclusion in Annex XIV? What are these regulatory options and why would they better address the concerns?

Other remarks

1. Would you like to provide additional comments/information on the possible socio-economic impacts?

\*\*\*\*\*